Pages that link to "Q38694283"

The following pages link to The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites (Q38694283):

Displaying 48 items.

• Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics (Q30462417) (← links)
• Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing (Q33580506) (← links)
• Developments with targeted enzymes in cancer therapy (Q33745133) (← links)
• Hypoxia-Specific Cytotoxins in Cancer Therapy (Q33862670) (← links)
• Antibody-directed enzyme prodrug therapy (ADEPT): a review (Q33933108) (← links)
• Targeted prodrug design to optimize drug delivery (Q34461985) (← links)
• Antibody-directed enzyme prodrug therapy (ADEPT) for cancer (Q34577226) (← links)
• Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network. (Q35087333) (← links)
• Advances in pretargeting biotechnology (Q35555181) (← links)
• Principles of antibody therapy (Q35660057) (← links)
• Choriocarcinoma. A model for tumour markers (Q36112327) (← links)
• Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro (Q36134970) (← links)
• In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy (Q36314064) (← links)
• Neuropeptide growth factors (Q36535839) (← links)
• In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein (Q36891698) (← links)
• Modern chemotherapeutic regimens in the management of aggressive non-Hodgkin lymphoma: Can they be improved? (Q37085507) (← links)
• Systemic immunotoxin therapy of cancer: advances and prospects (Q37359369) (← links)
• Monoclonal antibodies in diagnosis and therapy (Q37755851) (← links)
• Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination (Q38979784) (← links)
• Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma (Q39697849) (← links)
• The chemotherapy of colon cancer (Q40423904) (← links)
• Clinical issues in antibody design. (Q40475415) (← links)
• ADEPT and related concepts (Q40517119) (← links)
• Antibody-directed enzyme prodrug therapy (Q40589853) (← links)
• 5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy (Q40751291) (← links)
• The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). (Q40848135) (← links)
• Antibody-directed enzyme prodrug therapy (ADEPT). (Q40912787) (← links)
• Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application (Q41671705) (← links)
• Novel therapeutic strategies to selectively kill cancer cells. (Q41713799) (← links)
• The second Bagshawe lecture. Matching basic research to the management of cancer: the view from the other side of the fence (Q42220063) (← links)
• Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice (Q42383905) (← links)
• Strategies in antibody therapy of cancer (Q43758820) (← links)
• DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767. (Q44058245) (← links)
• Activation of Prodrugs by Antibody-Enzyme Conjugates (Q44184547) (← links)
• Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? (Q44298637) (← links)
• Synthesis and preliminary cytotoxicity study of glucuronide derivatives of CC-1065 analogues (Q44356937) (← links)
• Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT). (Q44804430) (← links)
• An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation. (Q53197611) (← links)
• Targeting enzymes to cancers--new developments. (Q53619323) (← links)
• Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds (Q54307101) (← links)
• Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial (Q56574975) (← links)
• SYNTHESIS OF CHLORAMPHENICOL AND MANDELONITRILE GALACTOSE-CONTAINING PRODRUGS (Q63369490) (← links)
• Engineering Antibodies for Therapy (Q67470988) (← links)
• Activation of prodrugs by targeted enzymes (Q67904832) (← links)
• Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts (Q72208052) (← links)
• The fate of antibodies and their radiolabels bound to tumor cells in vitro: the effect of cross-linking at the cell surface and of anti-idiotype antibodies (Q72875309) (← links)
• Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate (Q73427503) (← links)
• Intensely Cytotoxic Anthracycline Prodrugs: Glucuronides (Q73958943) (← links)